Nanotherapeutics in Cancer Vaccination and Challenges

Mahfoozur Rahman is an Assistant Professor at the Department of Pharmaceutical Sciences, Faculty of Health Science, Sam Higginbottom University of Agriculture, Technology & Sciences (SHUATS), Allahabad, India. He has authored more than 130 publications in peer-reviewed journals, 30 book chapters, seven books, and four articles in international magazines with various publishers. He has a Google Scholar h-index of 27 and over 1700 citations to his credit. He also serves on the editorial boards and as guest editor for several journals. He has received travel grants from various international congresses, such as IAPRD, MDS, Nano Today, KSN and WCN, on the basis of his research work and contribution in the field. Sarwar Beg, PhD is currently serving as AMS-DBT Newton International Fellow at University of Central Lancashire, UK, and working in the area of glioblastoma research using targeted nanomedicines. He is also serving as the Assistant Professor at Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi. He has over a decade of teaching and research experience in the field of pharmaceutics and biopharmaceutics, especially in the development of novel and nanostructured drug delivery systems using Quality-by-Design paradigms with core expertise in computational pharmaceutics, experimental designs and multivariate statistical techniques. He has authored over 200 publications, 60 book chapters, 15 books, 03 Indian patent applications and H-Index of 40 with over 5400 citations to his credit. Dr. Waleed Hassan Almalki is an associate professor of pharmacology at the college of pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia. He earned his doctoral degree from the University of Glasgow, United Kingdom having a dissertation on ocular pharmacology. His current research is focused on the broad areas of host-virus networks in hepacivirus C disease progression as well as host-virus genes expression during oxidative stress, hepatic steatosis, fibrosis, and hepatocellular carcinoma. He is also enthusiastically involved in the studies of tyrosine kinase inhibitors for the treatment of breast and colon cancer, in the Saudi population. Dr. Waleed has published many research and review articles in peer-reviewed international journals on HCV pathogenesis, treatment and drug designing as well as edited various book chapters about pathological angiogenesis, pharmacological assays and infectious disease epidemiology. Dr. Hani Choudhry is an Associate Professor of Genomics and the Head of Cancer and Mutagenesis Unit at the King Fahd Center for Medical Research in King Abdulaziz University (KAU), Saudi Arabia. Dr. Choudhry completed his DPhil in Clinical Medicine in Prof. Sir Peter Ratcliffe (Nobel Laureate 2019)’s lab at the Wellcome Trust Center for Human Genetics, University of Oxford, UK. Dr. Choudhry has received a number of international and prestigious awards including two AACR Scholar-in-Training Award, the Susan G. Komen for the Cure Award, the ASHG/Charles J. Epstein Trainee Award for Excellence in Human Genetics Research (SF), the Professional Achievement Award and the National Cancer Research Institute (NCRI) Prize Award. He was awarded by the British Embassy and the UAE International Genetic Disorders Prevention Award- Scientific Excellence Award in GCC. Dr. Choudhry’s current scientific interests focus on developing genomic technologies, and the integration of both clinical and pathological information with data generated from high-throughput molecular techniques. His work addresses the impact of genome and epigenome heterogeneity on the biology and clinical behaviour of diseases. In addition, he is leading a number of initiatives on artificial intelligence (AI) powered genome and drug discovery.

• 1. Cancer vaccines: Past, present and future2. Inorganic Nanoparticulate Carriers in management of Cancer: Theranostic and Toxicity Apprehension3. Recent developments in cancer vaccines: Where are we?4. Application of Nanotechnology assisted devices in cancer treatment5. Protein Based Nanocarriers as a Potent Drug Delivery Vehicle for Cancer Therapy6. Nanoparticle-based manipulation of antigen-presenting cells for cancer immunotherapy7. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies8. Peptide based anticancer targeted therapeutics: State of the Art9. Polyplexes-based delivery systems for cancer vaccine delivery10. Lipopolyplexes-based delivery system for cancer vaccine delivery11. Inorganic nanoparticulate carriers in cancer vaccination12. Functional nanomaterials and nanocomposites in cancer vaccines13. DNA vaccines for cancer treatment: Challenges and promises14. mRNA-based nanovaccines as newer treatment modalities in cancer15. Cancer immunotherapy: Moving forward with peptide T cell vaccines16. Product development and scale-up challenges in cancer vaccine development17. Regulatory landscape in the approval of cancer vaccines18. Cross-Presentation-based Nanovaccine for Cancer Immunotherapy19. Immunotherapy based cancer Vaccines: State of the art20. Therapeutics peptides in Anticancer therapy21. Inorganic Nanoconjugates For Cancer Theragnosis